PROTHENA CORP PUBLIC LTD CO current report, 05 April 2017

Full document

Business Context and Reporting Period

Company: Prothena Corporation Public Limited Company
Filing Type: Form 8-K (Current Report)
Date of Report: April 5, 2017
Event: Entry into a Material Definitive Agreement with Boehringer Ingelheim Biopharmaceuticals GmbH ("BI").

Key Financial Metrics

This filing reports a contractual agreement rather than financial performance results. Consequently, the document does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Agreement Terms

On April 5, 2017, Prothena subsidiaries entered into a Letter Agreement with BI, effective March 31, 2017. Key terms include:

  • Products: The agreement covers manufacturing capacity for NEOD001 (investigational monoclonal antibody for AL amyloidosis) and PRX003 (investigational monoclonal antibody for inflammatory diseases), plus potential additional biologics.
  • Capacity and Purchase Commitments: BI committed to specified maximum manufacturing capacities for 2018–2027. Prothena committed to purchase specified minimum quantities at agreed prices. These commitments are binding for the years 2018 through 2024.
  • Future Negotiations: The parties agreed to negotiate a new Master Technical Transfer and Supply Agreement ("New MSA") to replace the existing 2010 agreement and the current Letter Agreement. The New MSA is intended to expire on December 31, 2027.
  • Flexibility: BI may reduce capacity commitments under specified circumstances, subject to cost-sharing for technology transfer. Prothena may reduce purchase commitments subject to cancellation payments unless BI utilizes the unused capacity.

Guidance, Risks, and Termination

Termination Rights:

  • Either party may terminate for uncured material breach or insolvency.
  • Prothena may terminate for convenience, adverse government notices, clinical events, or limited regulatory approval of NEOD001 resulting in lack of demand.
Risks and Contingencies:
  • The agreement is contingent on the successful negotiation of the New MSA.
  • Financial obligations are subject to adjustments and potential cancellation payments if Prothena reduces purchase commitments.
  • Certain portions of the agreement are subject to a Confidential Treatment Request.
Management Commentary: The filing states the agreement secures manufacturing capacity for clinical development and potential commercial supply but does not include forward-looking financial guidance.

Investor Verification Checklist

  • Verify the specific binding minimum purchase quantities and agreed prices for 2018–2024 once the full agreement is filed as an exhibit to the Form 10-Q.
  • Monitor the progress of negotiations for the New MSA intended to replace the current Letter Agreement.
  • Assess the clinical development status of NEOD001 and PRX003, as regulatory outcomes directly impact Prothena's ability to utilize the reserved capacity.
  • Review the specific cost-sharing limits and cancellation payment formulas regarding capacity reduction.